Cargando…
Tau as a Biomarker of Neurodegeneration
Less than 50 years since tau was first isolated from a porcine brain, its detection in femtolitre concentrations in biological fluids is revolutionizing the diagnosis of neurodegenerative diseases. This review highlights the molecular and technological advances that have catapulted tau from obscurit...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266883/ https://www.ncbi.nlm.nih.gov/pubmed/35806324 http://dx.doi.org/10.3390/ijms23137307 |
_version_ | 1784743579254521856 |
---|---|
author | Holper, Sarah Watson, Rosie Yassi, Nawaf |
author_facet | Holper, Sarah Watson, Rosie Yassi, Nawaf |
author_sort | Holper, Sarah |
collection | PubMed |
description | Less than 50 years since tau was first isolated from a porcine brain, its detection in femtolitre concentrations in biological fluids is revolutionizing the diagnosis of neurodegenerative diseases. This review highlights the molecular and technological advances that have catapulted tau from obscurity to the forefront of biomarker diagnostics. Comprehensive updates are provided describing the burgeoning clinical applications of tau as a biomarker of neurodegeneration. For the clinician, tau not only enhances diagnostic accuracy, but holds promise as a predictor of clinical progression, phenotype, and response to drug therapy. For patients living with neurodegenerative disorders, characterization of tau dysregulation could provide much-needed clarity to a notoriously murky diagnostic landscape. |
format | Online Article Text |
id | pubmed-9266883 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92668832022-07-09 Tau as a Biomarker of Neurodegeneration Holper, Sarah Watson, Rosie Yassi, Nawaf Int J Mol Sci Review Less than 50 years since tau was first isolated from a porcine brain, its detection in femtolitre concentrations in biological fluids is revolutionizing the diagnosis of neurodegenerative diseases. This review highlights the molecular and technological advances that have catapulted tau from obscurity to the forefront of biomarker diagnostics. Comprehensive updates are provided describing the burgeoning clinical applications of tau as a biomarker of neurodegeneration. For the clinician, tau not only enhances diagnostic accuracy, but holds promise as a predictor of clinical progression, phenotype, and response to drug therapy. For patients living with neurodegenerative disorders, characterization of tau dysregulation could provide much-needed clarity to a notoriously murky diagnostic landscape. MDPI 2022-06-30 /pmc/articles/PMC9266883/ /pubmed/35806324 http://dx.doi.org/10.3390/ijms23137307 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Holper, Sarah Watson, Rosie Yassi, Nawaf Tau as a Biomarker of Neurodegeneration |
title | Tau as a Biomarker of Neurodegeneration |
title_full | Tau as a Biomarker of Neurodegeneration |
title_fullStr | Tau as a Biomarker of Neurodegeneration |
title_full_unstemmed | Tau as a Biomarker of Neurodegeneration |
title_short | Tau as a Biomarker of Neurodegeneration |
title_sort | tau as a biomarker of neurodegeneration |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266883/ https://www.ncbi.nlm.nih.gov/pubmed/35806324 http://dx.doi.org/10.3390/ijms23137307 |
work_keys_str_mv | AT holpersarah tauasabiomarkerofneurodegeneration AT watsonrosie tauasabiomarkerofneurodegeneration AT yassinawaf tauasabiomarkerofneurodegeneration |